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Cytokine signaling is triggered by a hormone-induced receptor aggregation process. IL-13 employs an
unconventional sequence of steps for assembling its signaling complex to trigger activation and for turning
it off. Both these processes involve some unusual molecular recognition features, as discussed by Lupardus
et al. (2010).To paraphrase a noted contemporary
philosopher: ‘‘.there are things we know
we know. we know there are some
things that we don’t know. But there are
also unknown unknowns—the ones we
don’t know we don’t know.’’ A great
example of how this plays out in bio-
logy is in the study of molecular recogni-
tion mechanisms that govern ligand-
induced receptor activation. Moving up
the ‘‘learning curve’’ has required con-
stant revisions of supposed ‘‘known-
knowns,’’ as well as the addition of new
known-unknowns. However, there is no
question that progress has quickened
with the availability of high-resolution
structures of numerous ligand-receptor
complexes coupled with vast amounts of
complementary functional and biophys-
ical data.
Among the many hormone ligand-
receptor systems with crystal structures
available, the class 1 cytokine superfamily
of hormones and receptors is arguably
the most extensively studied with regards
to structure-function relationships and the
molecular recognition elements that pro-
mote protein-protein interactions. This
large family includes most of the interleu-
kins (IL), as well as several big players
in drug therapy such hGH, EPO, and
GM-CSF. The basis for triggering the
first step of signaling, hormone-mediated
receptor aggregation, is similar across
all members of the superfamily. How-
ever, the molecular strategies employed
vary widely; some receptors function
in the context of homodimer clusters,
while others organize in hetero-oligomeric
complexes that include a number of dif-
ferent receptor subtypes.
The crystal structure of the human
growth hormone (hGH) and the extracel-
lular domain (ECD) of its receptor (hGHR)
solved by de Vos and colleagues in theearly 1990s revolutionized thinking in
the field about the composition and
mechanism of active cytokine signaling
complexes (de Vos et al., 1992). In the
structure, the hormone was bound
between two copies of the receptor ECD
on opposite faces of its asymmetric
structure in a completely unanticipated
fashion. There had been no previous
suggestion that a cytokine could effec-
tively homodimerize the receptor ECDs
by itself, an impressive feat facilitated by
the ability of the same receptor (using
the same set of residues) to bind to two
topographically distinct sites while simul-
taneously forming inter-ECD contacts.
Complexes involving receptor hetero-
oligomerization, on the other hand, face
a set of different requirements and molec-
ular recognition challenges.
The contribution by Lupardus et al.
(2010) in this issue provides some impor-
tant revisions and insights into two
unifying structure-function traits that are
characteristic of virtually all cytokine-
receptor interactions. The first is that
the asymmetric nature of most cytokines
leads to the generation of receptor bind-
ing sites with different binding potencies.
This site-1/site-2 binding paradigm, first
noted in the hGH/hGH-R complex (Cun-
ningham et al., 1991), is a driving feature
of cytokine signaling. Active receptor
signaling complexes are formed in a
controlled sequential step-wise manner,
with site-1 usually exhibiting a much
higher affinity than site-2, and therefore
being occupied first. The second unifying
trait is the utilization of binding ‘‘hot-
spots’’ (Clackson and Wells, 1995), which
are ubiquitous features of virtually all
protein-protein interactions. In systems
where a component may have multiple
binding targets, as is the case for a
number of cytokine-receptor complexesStructure 18, March 10, 2010(Wang et al., 2009), these hot spots are
required to have characteristics that
maintain both specificity and cross-reac-
tivity. In fact, there are cases where
a particular conserved interaction will be
critical in one interface while acting as
a mere bystander in another.
To set up the story described here, both
IL-4 and IL-13 form signaling complexes
by utilizing the same two receptors, with
site-1 binding to the IL-4Ra receptor and
site-2 binding to the IL-13Ra1 receptor
(LaPorte et al., 2008). With that said,
important differences exist in the progres-
sion of the steps leading to their active
receptor heterodimers. These differences
are driven by the relative affinity differ-
ences between site-1 and site-2 for each
cytokine. For the IL-4 /IL-4Ra/IL-13Ra1
complex, it’s the classic case: the site-1
mediated IL-4/IL4Ra interaction is high
affinity (KD 1nM), and binding to site 2
(KD 500nM) occurs only after the binary
IL-4/IL4Ra complex has formed (LaPorte
et al., 2008). In contrast, there is a role
reversal for the IL-13 complex; IL-13
does not bind to IL-4Ra at site-1 unless
IL-13Ra1 is already bound at site-2.
Here, the site-1/ site-2 paradigm is flip-
ped, and this inverted sequence of events
has biological implications.
So how does IL-13Ra1 bind IL-13 at
site-2 first? The answer is that it cheats.
While most cytokine receptors use two
fibronectin III domains in tandem (com-
monly referred to as a cytokine-binding
homology region [CHR]), IL-13Ra1 has
an additional N-terminal Ig domain that
interacts with an additional ‘‘site-3’’
region on the hormone (LaPorte et al.,
2008). Therefore, site-2 is really a combi-
nation of a ‘‘traditional’’ site-2 plus site-3,
and these interactions produce a relatively
high level of affinity between IL-13 and
IL-13Ra1 (20 nM). But the plot thickens.ª2010 Elsevier Ltd All rights reserved 275
Figure 1. IL-13 Interface with the ECD
(Left) IL-13Ra1. IL-13 molecule is represented in ribbon form and the receptor ECD is represented as
a surface. The three IL-13 hot-spot residue side chains (I14, K104, and F107) are shown in red. In the inter-
face with IL-13Ra1, K105 makes no direct contacts and there is a large depression in the interface, which
is partially filled by R108.
(Right) IL-13Ra2. IL-13 hot-spot residues basically make the same interactions with IL-13Ra2, but are
about 10-fold more sensitive to alanine substitutions. YR207 of the receptor forms a large hydrophobic
interaction with K105 (red arrow). Likewise, R108 forms extensive van der Waals and H-bonding interac-
tions; however, in both cases alanine substitutes produced little or no effect on binding.
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13Ra2, that Lupardus et al. (2010) show
binds IL-13 in a similar manner at site-
2+3 with an affinity for IL-13 nearly five
orders of magnitude higher (considerably
< 1 pM) than IL-13Ra1. This sub-picomo-
lar affinity makes the IL-13/IL-13Ra2
interaction one of the highest affinities
reported for a protein-protein interaction.
While the question of whether an IL-13/
IL-13Ra2 complex can signal remains
a matter of debate (Tabata and Khurana
Hershey, 2007), most bets are on it being,
at least in part, a decoy that outcompetes
IL-13Ra1 for the cytokine. Once IL-13
binds IL-13Ra2, game over—the hormone
becomes incapacitated. This rather
simple mechanism of regulation is appar-
ently effective, with IL-13Ra2 knockout
mice showing a phenotype suggestive of
excessive IL-13 signaling (Wood et al.,
2003).
So what is the source of IL-13Ra2’s
extraordinary affinity? Acknowledging
that the database is still relatively small,
there are surprisingly few noted examples
of ultra-high affinity natural protein-
protein interactions. In an attempt to find
an answer to this question, the authors
functionally characterized the site-2 and
site-3 receptor binding interfaces on
IL-13. This was achieved using a combi-
nation of surface plasmon resonance
and isothermal titration calorimetry to
compare the affinity of the wild-type inter-276 Structure 18, March 10, 2010 ª2010 Elseactions of IL-13 with IL-13Ra1 and
IL-13Ra2 to IL-13 mutants with interface
residues individually mutated to alanine.
These experiments were not straightfor-
ward, due to the fact that the ultra-high
affinity of IL-13Ra2 for IL-13 challenges
the limits of detection of the techniques
used. Nevertheless, it is clear that there
are three principal shared hot-spot resi-
dues (I14, K104, and F107) that form
a patch between helices A and D in the
center of the site-2 interface.
Apart from these hot-spot residues,
where does IL-13Ra2 pick up its addi-
tional affinity? One of the most notable
differences in the site-2 interface is the
interaction of the domain 2 EF loop of
IL-13Ra2 with IL-13, an interaction that
is absent in the IL-13/IL13Ra1 structure.
This loop fills a depression in the interface
and positions Y207 of the loop to make
a significant hydrophobic contact with
the aliphatic portion of the IL-13 K105
side chain (Figure 1). Compared to the
other hot-spot interactions, this interac-
tion looked to be a very promising candi-
date as a major player in IL-13Ra2
binding, but the K105A mutant produced
only a 10-fold effect on affinity. A similar
case was seen for R108 when the bind-
ing of IL-13 mutants to IL-13Ra2 was
analyzed. The aliphatic portion of R108
is buried in a groove created by the
domain 2 EF and domain 3 BC loops,
with hydrogen bonding interactions medi-vier Ltd All rights reservedated by the terminal guanidinium. This
residue seemed like a prime candidate
for making up part of the IL-13 binding
hotspot; yet when R108 was mutated to
alanine, no effect on binding to IL-13Ra2
was observed. Stranger yet, even though
R108 seems to be a peripheral contact in
the IL-13/IL-13Ra1 structure, a 1000-fold
decrease in affinity was observed for
the interaction of the IL-13 R108A mutant
with IL-13Ra1. Obviously a more com-
plete picture awaits an Ala-scan of the
IL-13Ra2 interface itself.
Protein engineers practiced in manipu-
lating binding interfaces are hardened to
the reality that features such as hydro-
phobic burial and electrostatic interac-
tions are not always reliable metrics of
binding affinity. There are often numerous
‘‘bystander’’ interactions that would seem
upon inspection to contribute as much as
those in a hot-spot region, but instead are
energetically neutral. Yet as accustomed
as we’ve become to being surprised
about how the energetics play out in
protein-protein interactions, the magni-
tude of the effects seen in the IL-13Ra2
binding is nothing less than astounding.
Consequently, studies like this one are
a touchstone to the reality that there
remain many known-unknowns, and that
the most apparent known-known is that
we have a long way to go to understand
protein-protein interactions at the molec-
ular level.REFERENCES
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